Daiichi-Lilly Effient Anti-Clotter Still Under U.S. FDA Review
This article was originally published in PharmAsia News
U.S. FDA has delayed its decision once again on whether to approve the Effient (prasugral) drug developed by Daiichi Sankyo and Eli Lilly. The anti-clotting drug is considered to be potentially risky. An agency review of data originally was due in September, but it remains uncompleted despite expectations by the companies. The companies said FDA has said nothing about its review, but noted "recent media speculation" it would have been completed. They said they still are in discussions with FDA. (Click here for more - a subscription may be required
You may also be interested in...
Results of three-year study conducted at 17 Canadian sites suggest that e-cigarettes use combined with counseling significantly increased abstinence from smoking cigarettes compared to receiving counseling alone.
Cambridge Nutraceuticals - which develops dietary supplements that have “proven clinical benefits” - has snapped up UK-based Prime Fifty to enhance its offering with products specifically designed for the over 50s.
Shanghai Henlius Biotech has begun dosing in a Phase I trial for its HLX14 planned biosimilar version of denosumab. Multiple biosimilar developers are vying to take a slice of the market for rivals to Amgen’s Xgeva/Prolia original.